• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Pulmonology

Soy isoflavone supplement yields no improvement in poorly controlled asthma

byPriyanka Vedak
May 26, 2015
in Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial of individuals with poorly controlled asthma, soy isoflavone supplementation was not associated with either symptomatic improvement or improvements in lung function when compared to placebo.

2. There was no significant difference in adverse events in the soy isoflavone supplement and placebo groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Prior studies have suggested an association between soy isoflavone supplementation and asthma severity via the modulation of the eosinophil leukotriene C4 synthesis pathway, but have not had sufficient power to clearly characterize this association. The authors of this study therefore conducted a randomized controlled trial on individuals with poorly controlled asthma assessing soy isoflavone supplementation versus placebo. The authors found that soy isoflavone supplementation was not associated with either symptomatic improvement or improvements in lung function when compared to placebo. Of the few serious adverse events reported, there was no significant difference in incidence between the soy isoflavone supplement group and the placebo group.

Limitations of this study included its limited intervention period of 6-months, which may have been inadequate to capture potential long-term benefits of soy isoflavone supplementation. Additionally, the individuals included in this study largely did not demonstrate evidence of inflammation, either systemic of airway. The effect of soy isoflavone supplementation on this subset of asthma patients is therefore unknown. At this time, however, there is no clear evidence supporting the use of soy isoflavone supplementation in poorly controlled asthma.

Click to read the study, published today in JAMA

Relevant Reading: Diet and Asthma

RELATED REPORTS

Comparison of systemic corticosteroids with and without nebulized budenoside for management of severe acute asthma

Albuterol-budesonide combination efficacious for asthma exacerbation rescue

Oral gefapixant reduces frequency of refractory or unexplained chronic coughs

In-Depth [randomized controlled trial]: This study involved 19 sites in a randomized controlled trial and randomized individuals in a 1:1 distribution to receive either a soy isoflavone supplement (n=182) or placebo (n=185) twice daily for 6 months. Included individuals were 12 years of age or older and demonstrated poorly controlled asthma as measured by one of a number of measures, including pulmonary function testing while taking a controller medication. The primary outcome of FEV1 was not significantly different between the two groups after 24 weeks (change of 0.03 L, 95%CI -0.01 to 0.08 L in the placebo group vs. change of -0.001 L, 95%CI -0.07 to 0.07 L in the soy isoflavone group). There was additionally no difference between the two groups in the Marks Asthma Quality of Life Questionnaire (-4.30, 95%CI -6.07 to -2.54 in the placebo group vs. -2.99, 95%CI -4.37 to -1.24 in the soy isoflavone group) or Asthma Control Test (ACT) scores (1.98, 95%CI 1.42 to 2.54 in the placebo group vs. 2.20, 95%CI 1.53 to 2.87 in the soy isoflavone group). There was no significant difference in adverse events between the soy isoflavone supplement group (n=14) and placebo group (n=12).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: asthma
Previous Post

Duration of dual-antiplatelet therapy may affect risk of stent complications

Next Post

Subclinical hyperthyroidism associated with hip and any fracture risk

RelatedReports

Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Emergency

Comparison of systemic corticosteroids with and without nebulized budenoside for management of severe acute asthma

August 3, 2022
Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Emergency

Albuterol-budesonide combination efficacious for asthma exacerbation rescue

June 21, 2022
Masks for personal protection for SARS-CoV-2 infection
Chronic Disease

Oral gefapixant reduces frequency of refractory or unexplained chronic coughs

April 5, 2022
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Chronic Disease

Reliever-triggered inhaled glucocorticoid therapy in among Black and Latinx adults with asthma

March 9, 2022
Next Post
Statin therapy does not prevent osteoporotic fractures [JUPITER trial]

Subclinical hyperthyroidism associated with hip and any fracture risk

Heparin bridging may increase bleeding without preventing recurrent thromboembolism

Heparin bridging may increase bleeding without preventing recurrent thromboembolism

Blood type correlates with egg reserve in infertile women

Arterial embolization successfully treats bleeding in anticoagulated patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Management of uncomplicated urinary tract infections amongst women in the United States Military Health System highly concordant with guidelines
  • Gout flares associated with a transient increase in subsequent risk of cardiovascular events
  • Litifilimab associated with reduced disease severity in patients with cutaneous lupus erythematosus
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.